Key result
Spironolactone treatment abolished the significant correlation between PAI-1 antigen and serum aldosterone observed during baseline and hydrochlorothiazide treatment (r2=0.13; P=0.33).
Why the study?
Does spironolactone alter the relationship between aldosterone and PAI-1 in male hypertensive subjects?
Population
9 male hypertensive subjects
Comparison
Spironolactone for 2 weeks vs Baseline and hydrochlorothiazide for 2 weeks
Design
Cohort
Follow-up
7 weeks
Authors
Loading...
Spironolactone abolishes aldosterone-PAI-1 correlation in male hypertensives; confirms mineralocorticoid receptor blockade modulates this pathway.
Does spironolactone alter the relationship between aldosterone and PAI-1 in male hypertensive subjects?
Sawathiparnich et al. (2002) studied Hypertension (n=9). Spironolactone vs. Hydrochlorothiazide (25 mg plus 20 mmol KCl/d) and baseline was evaluated on Plasminogen activator inhibitor-1 (PAI-1) antigen levels and correlation with serum aldosterone. Spironolactone treatment abolished the significant correlation between PAI-1 antigen and serum aldosterone observed during baseline and hydrochlorothiazide treatment (r2=0.13; P=0.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: